The SAVANNAH study showed that targeting MET amplification after TKI failure is only effective with stringent diagnostic criteria (e.g., IHC 3+ in >90% of cells). Lower cutoffs lead to poor outcomes, highlighting the need for precise biomarker testing to select patients for this therapy.

Landmark discoveries, like EGFR mutations, didn't start in a lab but with astute oncologists noticing patterns in how some patients responded to treatment while others didn't. This highlights that every patient interaction is a research opportunity, offering clues that can lead to the next scientific breakthrough.

Patients with EGFR-mutant NSCLC that transforms into small cell lung cancer show poor responses to new therapies like tarlatamab, which are highly effective in de novo small cell cancer. This highlights a distinct biology that requires different therapeutic strategies and dedicated clinical trials.

Features like brain metastases or p53 co-mutations are considered high-risk. However, about 75% of patients have at least one such factor, making the "high-risk" profile the norm, not the exception, and reinforcing the need for upfront combination therapy.

An individual tumor can have hundreds of unique mutations, making it impossible to predict treatment response from a single genetic marker. This molecular chaos necessitates functional tests that measure a drug's actual effect on the patient's cells to determine the best therapy.

When GIST progresses on therapy like imatinib, resistance is often heterogeneous. Different metastatic sites within the same patient can develop distinct secondary resistance mutations (e.g., an exon 13 mutation in the liver and an exon 17 in the peritoneum). This complicates subsequent treatment selection and underscores the value of comprehensive testing like ctDNA.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

The same cancer-driving mutation behaves differently depending on the cell's internal "wiring." For example, a drug targeting a mutation works in melanoma but induces resistance in colorectal cancer due to a bypass pathway. This cellular context is why genetic data alone is insufficient.

Before the LAURA trial, oncologists had strong data for using EGFR TKIs in metastatic and resectable settings but lacked evidence for the unresectable Stage 3 population receiving chemoradiation. LAURA filled this "awkward gap," confirming a long-held suspicion and harmonizing treatment strategy across disease stages.